Value
8.8/10data confidence 50%| Component | Sub-score |
|---|---|
| P/S | 8.9 |
| Fwd P/E | 7.3 |
| PEG | 10.0 |
- ▸Forward P/E: 17.1x
- ▸PEG: 0.13
- ▸Attractively valued
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
GLAS is a small specialty-pharma name with no usable price feed this run, cash burn alongside declining revenue, and a bottom-decile peer ranking, offset only by a perfect 4-quarter earnings beat streak.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
| Pillar | Expectation | Trend |
|---|---|---|
GLAS's price feed returned no data this run, which the engine flags as a hard blocker preventing any entry, target, or stop calculation. Warnings | A resumed, non-null price feed within the next reporting cycle should restore the ability to compute entry, target, and stop levels. | ↑Improving |
| CounterPersistent no-price data can also reflect a genuinely illiquid or thinly-traded name rather than a temporary feed gap. | ||
The company is cash-burning, with free cash flow at -15% of revenue, alongside revenue declining roughly 10% year over year. Quality breakdown | Free cash flow should turn less negative and revenue decline should moderate toward flat or positive. | →Stable |
| CounterA cash-burning small specialty-pharma name can still be pre-revenue-inflection if it's investing in a near-term product launch, masking underlying trajectory. | ||
The company has beaten earnings estimates in all 4 of its last 4 quarters, with an average surprise near 99%, despite the broader quality concerns. Earnings | The beat streak should extend to a 5th consecutive quarter at the next earnings report. | →Stable |
| CounterBeats this large and consistent, paired with declining revenue, often reflect deliberately low guidance rather than genuine business strength. | ||
The stock ranks at the very bottom of its peer group, with a peer-rank score of 1.0 out of 10, reflecting broad relative underperformance versus comparable companies. Peer rank | The peer-rank score should climb out of the bottom decile as relative fundamentals or valuation improve versus peers. | ↑Improving |
| CounterA bottom-decile peer ranking in a single snapshot period can reflect a temporarily depressed sector-wide multiple rather than firm-specific weakness. | ||
CounterPersistent no-price data can also reflect a genuinely illiquid or thinly-traded name rather than a temporary feed gap.
CounterA cash-burning small specialty-pharma name can still be pre-revenue-inflection if it's investing in a near-term product launch, masking underlying trajectory.
CounterBeats this large and consistent, paired with declining revenue, often reflect deliberately low guidance rather than genuine business strength.
CounterA bottom-decile peer ranking in a single snapshot period can reflect a temporarily depressed sector-wide multiple rather than firm-specific weakness.
| Component | Sub-score |
|---|---|
| P/S | 8.9 |
| Fwd P/E | 7.3 |
| PEG | 10.0 |
| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 2.4 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.2 |
| Piotroski F | 4.4 |
| Component | Sub-score |
|---|---|
| Rev growth | 2.2 |
| EPS growth | 10.0 |
| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 0.5 |
| OBV | 1.0 |
| MA position | 2.5 |
| Volume | 6.5 |
| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
| Component | Sub-score |
|---|---|
| value rank | 6.0 |
| quality rank | 1.3 |
| growth rank | 1.5 |
| Component | Sub-score |
|---|---|
| bollinger | 8.9 |
| support resistance | 9.5 |
| 52w position | 0.0 |
| gap | 6.0 |
| Component | Sub-score |
|---|---|
| days to cover | 10.0 |
| volatility | 0.0 |
| put call | 10.0 |
| beta | 8.4 |
| debt equity | 8.2 |
| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| surprise avg | 10.0 |
Market cap $363M below $400M minimum. Not in investable universe.
L1:HARD_BLOCK:MARKET_CAPSetupOversold Bounce — Oversold RSI 5, near Bollinger lower, volume surge
EdgeInst Constrain — Small cap ($0.4B) below institutional reach
SuitabilitySpeculative — Drawdown -71% (>40% off 52w high)
The HOLD_IF_HOLDING verdict reflects the MOMENTUM gate's 2.7<4.5 outcome against Value at 8.8 and asymmetric R:R of 0.00.
The strongest dimensions are Value at 8.8, Catalyst at 8.3, and Insider at 7.3; the weakest are Quality at 1.7, Momentum at 2.7, and Peer rank at 3.9. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
Trip ifPrice data remains unavailable for more than 2 consecutive engine runs.
Trip ifFree cash flow stays below 0% of revenue for 2 more consecutive quarters.
Trip ifBeat count falls below 4 out of the trailing 4 quarters after the next earnings report.
Trip ifPeer-rank score stays below 2.0 out of 10 for 2 more consecutive quarters.